How Microbiotica Developed MB097, Live Bacterial Therapeutic that Could Boost Cancer Treatments

Ghaith Bakdash described how Microbiotica discovered a specific microbiome signature in patients responder to immune-oncology drugs such as anti-PD1 / PDL1 and developed a new bacterial consortium.

Engineered microbiota may be used for drug delivery

The findings of a recent study suggest that engineered native gut bacteria could be employed to help treat certain diseases such as diabetes.

Some artificial sweeteners may alter the microbiota, affect blood glucose control

A recent study suggests that the microbiome changes in response to human consumption of non-nutritive sweetener may induce glycemic changes in consumers in a personalized manner.

Skin Microbiome: How We Developed a New Probiotic to Treat Acne

Sarah Lebeer (Research professor, University of Antwerp) described how she and her colleagues developed a new probiotic topic formulation to treat Acne.

Lallemand Health Solutions gains new Canadian claims showing its probiotics can help formula-fed babies develop a similar microflora as to breast-fed ones

The intestinal microflora of infants should contain a high proportion of Bifidobacteria during their first year of life to be well preserved and balanced

Universal DX: Microbiome Signatures in Plasma Can Help Detect Early-Stage Colorectal Cancer

Company Presents Data at ESMO Congress Showing Link Between Gut Bacteria and Early Colorectal Cancer Detection

Babies acquire multi-drug-resistant bacteria within hours of birth

Antimicrobial resistant bacteria are present in newborns after just a few hours of life and they help to understand the routes of transmission of antibiotic-resistance genes.

Microbial signature may predict a person’s response to statins

The findings of a new research suggest that different responses to statins can be explained by the variation in the human microbiota.

Lesaffre Acquires Recombia Biosciences and Entry into the World of Synthetic Biology

The acquisition is the culmination of a strategic partnership initiated in 2020 to accelerate the development of yeasts for sustainable production of fermented ingredients.

How Bayer Consumer Healthcare is Involved in Microbiome Research

Holger Lenz discusses the interest of Bayer in the microbiome space during Microbiome Connect: Europe 2022.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top